lopinavir; ritonavir · Abbvie · NDA 021226, 021251, 021906
Kaletra
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Generic approved · ANDA 214696, Micro Labs · 021906-001Approved 11 Dec 2025Detected 25 Oct 2026Historical import
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 021226 · 001 · discontinued | capsule, oral | 133.3MG;33.3MG | open |
| 021251 · 001 · RLD | solution, oral | 80MG/ML;20MG/ML | open |
| 021906 · 001 · RLD | tablet, oral | 200MG;50MG | open |
| 021906 · 002 · RLD | tablet, oral | 100MG;25MG | open |